Search - tctmd.com

Displaying 401 - 413 of 413

Sort: Relevancy | Date

News Industry News

Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients

May 07, 2015

Presentation CADECI 2015

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Presenter: DR. JOSE LUIS LEIVA PONS

February 20, 2015

News Daily News

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Caitlin E. Cox

April 19, 2013

News Daily News

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Caitlin E. Cox

April 19, 2013

Presentation

Nuisance Bleeding with Prolonged Dual Antiplatelet Therapy After AMI and Its Impact on Health Status

Presenter: A. P. Amin

March 26, 2013

News Daily News

Una Dosis Alta de Aspirina tras una PCI Primaria aumenta las Hemorragias No observandose Beneficio Isquémico alguno

L.A. McKeown

December 19, 2012

News Daily News

High-Dose Aspirin After Primary PCI Increases Bleeding with No Ischemic Benefit

L.A. McKeown

December 19, 2012

Presentation

Safety and Efficacy of High- vs. Low-Dose Aspirin After Primary PCI in STEMI

Presenter: J. Yu

December 17, 2012

Presentation

Use of New-Generation Oral Anticoagulant Agents in Patients Receiving Antiplatelet Therapy After an ACS

Presenter: Andr?s Kom?csi

October 01, 2012

News Daily News

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

September 20, 2012

Presentation TCTAP 2012

Evidence-Based Pharmacotherapy Recommendations for PCI, NSTEMI, and STEMI:

Presenter: Gregg W. Stone

April 26, 2012

News Daily News

Antiplatelet Therapy Plus SSRI Spurs Bleeding After MI

Yael L. Maxwell

September 26, 2011

News Conference News

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

August 31, 2011

Advertisement

Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Rivaroxaban Added to Dual Antiplatelet Therapy Cuts Stent Thrombosis in ACS Patients

Rivaroxaban + Terapia Antiplaquetaria Doble Reducen la Trombosis del Stent en Pacientes víctimas de un SCA

Nuisance Bleeding with Prolonged Dual Antiplatelet Therapy After AMI and Its Impact on Health Status

Una Dosis Alta de Aspirina tras una PCI Primaria aumenta las Hemorragias No observandose Beneficio Isquémico alguno

High-Dose Aspirin After Primary PCI Increases Bleeding with No Ischemic Benefit

Safety and Efficacy of High- vs. Low-Dose Aspirin After Primary PCI in STEMI

Use of New-Generation Oral Anticoagulant Agents in Patients Receiving Antiplatelet Therapy After an ACS

Studies Suggest Less Stringent Dual Antiplatelet Use After DES

Evidence-Based Pharmacotherapy Recommendations for PCI, NSTEMI, and STEMI:

Antiplatelet Therapy Plus SSRI Spurs Bleeding After MI

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content